Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

Trial Profile

Sargramostim to Reverse Myeloid Dendritic Cell Deficiency

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Acute radiation syndrome; Alzheimer's disease; Bone marrow disorders; Chronic lymphocytic leukaemia; Neutropenia; Pneumococcal infections; Prostate cancer; Pulmonary alveolar proteinosis; Stem cell mobilisation
  • Focus Pharmacodynamics

Most Recent Events

  • 21 Sep 2018 Status hs been changed to discontinued.
  • 18 Sep 2018 Status changed from recruiting to completed.
  • 20 Oct 2017 Planned number of patients changed from 15 to 25.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top